Cancer genomics has fundamentally transformed our understanding of cancer biology and is driving the development of precision oncology — the use of genomic information to guide personalized cancer treatment decisions. By sequencing tumor genomes and comparing them to matched normal tissue, researchers and clinicians can identify somatic mutations, copy number alterations, structural variants, and gene fusions that drive cancer development, progression, and therapeutic resistance.

Large-scale cancer genomics projects including The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Pan-Cancer Analysis of Whole Genomes (PCAWG) have provided unprecedented insights into the genomic landscape of human cancers. This guide covers the key bioinformatics approaches and tools for cancer genomics analysis in 2026.

Somatic Variant Calling in Cancer

Identifying somatic mutations in tumor samples requires specialized variant calling approaches that can distinguish true tumor-specific mutations from germline variants and sequencing artifacts. Tumor-normal paired sequencing is the gold standard approach for sensitive and specific somatic variant detection.

  • Mutect2 — GATK somatic variant caller for tumor-normal analysis
  • Strelka2 — fast and accurate somatic SNV and indel calling
  • VarScan2 — somatic mutation and copy number detection
  • PURPLE — tumor purity, ploidy, and copy number estimation

Mutational Signature Analysis

Mutational signatures are characteristic patterns of somatic mutations caused by specific mutagenic processes including DNA repair deficiencies, carcinogen exposure, and endogenous mutational processes. Identifying mutational signatures provides insights into cancer etiology and can guide treatment decisions.

  • SigProfiler — comprehensive mutational signature extraction and fitting
  • MutationalPatterns — R package for mutational signature analysis
  • COSMIC signatures database — reference collection of known mutational signatures
  • deconstructSigs — fitting tumor mutational profiles to known signatures

Driver Gene & Pathway Analysis

Distinguishing cancer driver mutations from the large background of passenger mutations is a central challenge in cancer genomics. Computational methods for driver gene identification and pathway enrichment analysis help prioritize functionally important mutations for experimental validation and therapeutic targeting.

  • dNdScv — maximum likelihood method for cancer driver gene detection
  • MutSigCV — identifying significantly mutated genes in cancer cohorts
  • OncoKB & CIViC — clinical interpretation of cancer genomic variants
  • GSEA & ReactomePA — pathway enrichment analysis for cancer mutations

Precision Oncology & Clinical Applications

Cancer genomics analysis is increasingly being integrated into clinical oncology practice to guide treatment selection, monitor treatment response, and detect resistance mutations through liquid biopsy. Tumor mutational burden, microsatellite instability, and homologous recombination deficiency are now established genomic biomarkers used to guide immunotherapy and PARP inhibitor treatment decisions.

Circulating tumor DNA analysis from liquid biopsies is enabling non-invasive monitoring of cancer evolution, early detection of relapse, and real-time tracking of therapeutic resistance mechanisms without requiring repeat tumor biopsies.

The integration of multi-omics cancer data with clinical outcomes through machine learning is accelerating the discovery of novel prognostic biomarkers and predictive signatures for personalized cancer treatment selection.

Need Cancer Genomics Analysis?

At BioinformaticsNext, we provide comprehensive cancer genomics analysis services including somatic variant calling, mutational signature analysis, driver gene identification, and clinical variant interpretation. Our expert team supports precision oncology research and clinical genomics projects worldwide. Contact us today for a free consultation.